优化左心室辅助器件速度:心力衰竭临床医生的系统性审查
Yomary Jimenez1, Christina Tsai1, Fatima Mrizigue2
1Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, USA.
Future cardiology
|September 24, 2025
概括
优化左心室辅助装置 (LVAD) 速度对于心力衰竭患者至关重要. 目前的研究缺乏标准化的方法和全面的结果报告,需要进一步研究最佳实践.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 心脏衰竭管理的管理
背景情况:
- 左心室辅助装置 (LVAD) 改善了末期心力衰竭患者的生存率和生活质量.
- 最佳的LVAD速度对于有效的左心室卸载而无损害右心功能至关重要.
- 速度定位研究对于确定理想的LVAD设置至关重要.
研究的目的:
- 审查关于LVAD速度优化研究的现有文献.
- 为了确定LVAD速度定位的当前方法和报告结果.
- 突出在LVAD速度优化研究中需要标准化的方法.
主要方法:
- 在PubMed,Scopus和CINAHL数据库中进行了系统的文献搜索.
- 搜索术语包括LVAD的变体和速度优化/坡道研究.
- 包括到2025年4月发表的研究.
主要成果:
- 分析了22项涉及749名患者的研究,其中45%使用了Heart Mate 3设备.
- 评估的主要结果是死亡率,再入院,RV功能,速度变化和生活质量.
- 一个显著的局限性是研究对结果的报道差且不一致,64%的人报告了两个或更少的结果.
结论:
- 对于Heart Mate 3 LVAD,关于速度优化的标准化数据很少.
- 目前的研究缺乏统一的评估方法和结果报告.
- 需要进行前性研究,采用标准化速度优化协议和全面的结果措施,以建立最佳实践.
相关概念视频
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


